Primary and secondary prevention of stroke by antihypertensive drug treatment

References

• He J, Klag MJ, Wu Z, Whelton PK. Stroke in the People's Republic of China. II. Meta-analysis of hypertension and risk of stroke. Stroke 26,2228–2232 (1995).
   PubMed Web of Science ®Google Scholar
• Branner LL, Kanter DS, Manson JE. Primary prevention of stroke. N Engl. Med. 333,1392–1400 (1995).
   PubMedGoogle Scholar
• Prospective Studies Collaboration. Age- specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360, 1903–1913 (2002).
   PubMed Web of Science ®Google Scholar
• ••Describes the largest ever meta-analysis ofobservational studies on the relationship between mortality and blood pressure, and clearly shows that blood pressure is positively associated with mortality in all age groups.
   Google Scholar
• Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 349, 1269–1276 (1997).
   PubMed Web of Science ®Google Scholar
• Collins R, Peto R, MacMahon S et aL Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 335,827–838 (1990).
   Google Scholar
• Staessen JA, Gasowski J, Wang JG et aL Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 355, 865–872 (2000).
   PubMed Web of Science ®Google Scholar
• Liu L, Wang JG, Gong L et al. Comparison of active treatment and placebo in older patients with isolated systolic hypertension. J. Hypertens. 16, 1823–1829 (1998).
   PubMed Web of Science ®Google Scholar
• Wang JG, Staessen JA, Gong L, Liu L, for the Systolic Hypertension in China (Syst-China) Collaborative Group. Chinese trial on isolated systolic hypertension in the elderly. Arch. Intern. Med. 160,211–220 (2000).
   Google Scholar
• Wolf-Maier K, Cooper RS, Banegas JR et al. Hypertension prevalence and blood pressure levels in six European countries, Canada, and the United States. JAMA 289, 2363–2369 (2003).
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Cou11 AJ, Giles MF et aL Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 363, 1925–1933 (2004).
   PubMed Web of Science ®Google Scholar
• ••Shows that stroke incidence has decreasedover the last 20 years, mainly due to the use of blood pressure-lowering agents and other preventive treatments.
   Google Scholar
• Borhani NO, Mercuri M, Borhani PA et al. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS). A randomized controlled trial. JAMA 276, 785–791 (1996).
   PubMed Web of Science ®Google Scholar
• Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353,611–616 (1999).
   PubMed Web of Science ®Google Scholar
• National Intervention Co-operative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension 34, 1129–1133 (1999).
   PubMed Web of Science ®Google Scholar
• Hansson L, Lindholm LH, Ekbom T et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354, 1751–1756 (1999).
   PubMed Web of Science ®Google Scholar
• Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomised to double-blind treatment with long-acting calcium-channel blacker or diuretic in the International Nifedipine GITS Study: intervention as a Goal in Hypertensive Treatment (INSIGHT). Lancet 356,366–372 (2000).
   PubMed Web of Science ®Google Scholar
• Hansson L, Hedner T, Lund-Johansen P et al. Randomised trial of effects of calciumantagonists compared with diuretics and B-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet356, 359–365 (2000).
   PubMed Web of Science ®Google Scholar
• The ALLHAT Officers and Co-ordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 283,1967–1975 (2000).
   Google Scholar
• Zanchetti A, Agabiti Rosei E, Dal Pain C et aL The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens. 16,1667–1676 (1998).
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 39. Br. Med. J. 317, 713–720 (2000).
   Google Scholar
• Black HR, Elliott WJ, Grambsch P et aL Principal results of the Controlled ONset Verapamil INvestigation of Cardiovascular End points (CONVINCE) Trial. JAMA 289,2073–2082 (2003).
   PubMed Web of Science ®Google Scholar
• Dahl& B, Devereux B. Cardiovascular morbidity and mortality in the Losartan Intervention For End point reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359, 995–1003 (2002).
   Google Scholar
• Zanchetti A, Bond G, Hennig M et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 106,2422–2427 (2002).
   Google Scholar
• The ALLHAT Officers and Co-ordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blacker versus diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288,2981–2997 (2002).
   Google Scholar
• Wing LMH, Reid CM, Ryan P et aL A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl. Med. 348,583–592 (2003).
   PubMed Web of Science ®Google Scholar
• Lithell H, Hansson L, Skoog I et al. The study on cognition and prognosis in the elderly (SCOPE). Principal results of a randomised double-blind intervention trial. J Hypertens. 21,875–886 (2003).
   Google Scholar
• Frohlich ED. Treating hypertension. What are we to believe? N Engl. J. Med. 348, 639–641 (2003).
   PubMed Web of Science ®Google Scholar
• Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a meta-analysis. (Correction published Lancet 359,360 [2002]). Lancet358, 1305–1315 (2001).
   Google Scholar
• Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003.1 Hypertens. 21,1055-1076 (2003).
   Google Scholar
• Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br. Med. Bull. 50,272–298 (1994).
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Ibsen H, Dahl& B et aL Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For End point reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359, 1004–1010 (2002).
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. Br. Med. J. 317,703-713 (1998).
   Google Scholar
• Helgeland A. Treatment of mild hypertension: a five year controlled drug trial. Am. J Med. 69,725–732 (1980).
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with prior stroke or transient ischemic attack. Lancet 358, 1033–1041 (2001).
   PubMed Web of Science ®Google Scholar
• Carter AB. Hypotensive therapy in stroke survivors. Lancet 1,485–489 (1970).
   PubMed Web of Science ®Google Scholar
• Hypertension-Stroke Co-operative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA 229,409–418 (1974).
   PubMed Web of Science ®Google Scholar
• PATS Collaborative Group. Poststroke antihypertensive treatment study. A preliminary result. Chin. Med. J. 108, 710–717 (1995).
   PubMed Web of Science ®Google Scholar
• The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient isachemic attack or nondisabling stroke. Stroke 24,543–548 (1993).
   PubMed Web of Science ®Google Scholar
• Eriksson S, Olofsson BO, Wester PO, for the TEST Study Group. Atenolol in the secondary prevention of stroke. Cerebrovasc. Dis. 5,21–25 (1995).
   Google Scholar
• Amery A, Birkenhäger W, Brixko P et aL Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1349–1354 (1985).
   Google Scholar
• Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. Br. Med. J. 293, 1145–1151 (1986).
   PubMed Web of Science ®Google Scholar
• Dahl& B, Lindholm LH, Hansson L et aL Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 338, 1281–1285 (1991).
   Google Scholar
• MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. Br. Med. J. 304,405–412 (1992).
   PubMed Web of Science ®Google Scholar
• Medical Research Council Working Party. Medical Research Council trial of treatment of mild hypertension: principal results. Br. Med. J. 291,97–104 (1985).
   PubMed Web of Science ®Google Scholar
• SHEP Co-operative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265,3255–3264 (1991).
   Google Scholar
• Gong L, Zhang W, Zhu Y et al. Shanghai trial of nifedipine in the elderly (STONE). Hypertens. 14,1237–1245 (1996).
   Web of Science ®Google Scholar
• Curb JD, Pressel SL, Cutler JA et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 276,1886–1892 (1996).
   PubMed Web of Science ®Google Scholar
• Staessen JA, Fagard R, Thijs L et aL Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. (Correction published Lancet 350, N1636 [1997]). Lancet350, 757–764 (1997).
   Google Scholar
• Management Committee. The Australian Therapeutic Trial in Mild Hypertension. Lancetl, 1261–1267 (1980).
   Google Scholar
• US Public Health Service Hospitals Co-operative Study Group (McFate Smith WM). Treatment of mild hypertension: results of a 10-year intervention trial. Circ. Res. 40,1-98-1-105 (1977).
   Google Scholar
• Veterans Administration Co-operative Study Group on Antihypertensive Agents. Effect of treatment on morbidity in hypertension: results in patients with diastolic blood pressure averaging 115-129 mmHg. JAMA 202,116–122 (1967).
   PubMed Web of Science ®Google Scholar
• Tuomilehto J, Rastenyte D, Birkenhäger WH et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl. J. Med. 340, 677–684 (1999).
   PubMed Web of Science ®Google Scholar
• Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351,1755–1762 (1998).
   PubMed Web of Science ®Google Scholar
• MacMahon S, Sharpe N, Gamble G et al. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. J. Am. Coll. CardioL 36,438–443 (2000).
   PubMed Web of Science ®Google Scholar
• Teo KK, Burton JR, Buller CE etal. Long- term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis. The Simvastatiranalapril Coronary Atherosclerosis Trial (SCAT). Circulation 102,1748–1754 (2000).
   Google Scholar
• The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N EngL J. Med. 342, 145–153 (2000).
   PubMed Web of Science ®Google Scholar
• Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355,253–259 (2000).
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR et aL Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N Engl. J. Med. 345,851-860 poly
   Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N EngL J. Med. 345,861-869 (2001).
   Google Scholar
• Parving HH, Lehnert H, Bröchner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. N EngL J. Med. 345,870-878 (2001).
   Google Scholar
• Wang JG, Staessen JA. Conventional therapy and newer drug classes for cardiovascular protection in hypertension. J Am. Soc. NephroL 13 (Suppl. 3), S208—S215 (2002).
   Google Scholar
• Staessen JA, Wang JG, Birkenhäger WH. Outcome beyond blood pressure control? Eur. Heart J. 24,504–514 (2003).
   Google Scholar
• Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362, 782–788 (2003).
   PubMed Web of Science ®Google Scholar
• Dalmay F, Mazouz H, Allard J et al. NonATrreceptor mediated protective effect of angiotensin against acute ischaemic stroke in the gerbil. I Renin Angiotensin Aldosterone Syst. 2, 103–106 (2001).
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M et aL Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363, 2022–2031 (2004).
   PubMed Web of Science ®Google Scholar
• •Shows that amlodipine-based antihypertensive regimen controls blood pressure better and is more effective in cardiovascular prevention than varlsartan as the first-line drug.
   Google Scholar
• Schrier RW, Estacio RO, Esler A, Mehler E Effects of aggressive blood pressure control in normotensive Type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 61, 1086–1097 (2002).
   PubMed Web of Science ®Google Scholar
• Marre M, Lfevre M, Vasmant D et al. Determinants of elevated urinary albumin in the 4,937 Type 2 diabetic subjects recruited for the DIABHYCAR study in Western Europe and Northern Africa. Diabet. Care 23\(Suppl. 2), B40—B48 (2000).
   Google Scholar
• Dens JA, Desmet WJ, Coussement P et al. Usefulness of nisoldipine for prevention of restenosis after percutaneous transluminal coronary angioplasty (results of the NICOLE study). NIsoldipine in COronary artery disease in LEuven. Am. j Cardiol. 87, 28–33 (2001).
   Google Scholar
• Byington RB, Miller ME, Herrington D et al. Rationale, design, and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT). Am. Cardiol. 80, 1087–1090 (1997).
   PubMed Web of Science ®Google Scholar
• Pitt B, Byington RP, Furberg CD et aL Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 102, 1503–1510 (2000).
   PubMed Web of Science ®Google Scholar